Systemic levels of ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis.
BACKGROUND
The role of ceruloplasmin oxidase activity (COA) involving the interaction of oxidant and antioxidant balance in allergic diseases is still unknown.


OBJECTIVE
Our study was designed to examine the changes in COAs in severe persistent asthma-allergic rhinitis, new diagnosed allergic asthma-allergic rhinitis and allergic rhinitis patients.


METHODS
The study included 20 age- and sex-matched healthy individuals as control (Group I); Group II included 15 newly diagnosed allergic asthma-allergic rhinitis; Group III included 15 patients with severe persistent asthma-allergic rhinitis and in the fourth group there were 20 patients with allergic rhinitis. Group III was divided in two groups, severe persistent asthma-allergic rhinitis who were pre-(III-A) and post-treated (III-B) with omalizumab. Group IV was divided to two groups, pretreatment (IV-A) and posttreatment (IV-B) with specific subcutaneous immunotherapy modalities. All the posttreatment measurements were 12 months after the therapy. All the patients were assessed by the skin prick test, high sensitive C-reactive protein (hs-CRP) and COA.


RESULTS
There were significant differences between Group I and Groups III-A, III-B, IV-A and IV-B; Group II and Groups III-A, III-B, IV-A and IV-B; Group III-A and Groups III-B, IV-A and IV-B; Group III-A and Groups IV-A and IV-B; and Group IV-A and IV-B. Interestingly, there was a correlation between the hs-CRP and COA levels in Group III-A.


CONCLUSIONS
Our data suggest that hs-CRP and COA levels might be an indicator of an inflammation and important in revelation of patients with allergy related diseases, especially of asthma patients.
Internal Medicine, Allergy and Clinical Immunology Unit, Antalya Education and Research Hospital, Antalya, Turkey. adidyal@yahoo.com
Arzu Didem
AD
Yalcin
Saadet
S
Gumuslu
Gizem Esra
GE
Parlak
Atil
A
Bisgin
Mustafa
M
Yildiz
Aysegül
A
Kargi
Reginald M
RM
Gorczynski
D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D001249:Asthma / Q000097:blood* / Q000188:drug therapy; D002097:C-Reactive Protein / Q000378:metabolism; D002570:Ceruloplasmin / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D000069444:Omalizumab; D065631:Rhinitis, Allergic; D012221:Rhinitis, Allergic, Perennial / Q000097:blood* / Q000188:drug therapy; D013997:Time Factors
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D002097:C-Reactive Protein; D002570:Ceruloplasmin